Bood: Prediction and prevention of CNS recurrence in patients with extracellular natural killing/T-cell lymphoma

The incidence of recurrence of the central nervous system (CNS) was different from previously reported due to the improvement of the survival prognosis of patients with theof endocooma/T cellslymphoma (ENKTL) due to the improvement of l-tianamide enzyme non-rhymic chemotherapyIn this study,researchers aimed to identify the incidence and predictive markers of CNS recurrence in order to assess the need for medium-dose MTX (ID-MTX)to preventCNSThe records of 399 cases of training queue and 253 patients receiving non-ring chemotherapy were reviewed and analyzeddivided the patient into two groups, depending on whether the chemotherapy regimen has ID-MTX 2g/m2A CNS-PINK model (naturally killer lymphoma (PINK) prognosticindex (HR 2.908, p-0.03) was developed using a single point prediction of CNS recurrenceThe HR 4.161, p-0.001) and calculate the sum of the scores when the end of the lymph nodes is taken out of the boundaryCNS-PINK's high-risk population is defined as 2 pointsin the training and validation queue, the cumulative recurrence rate of CNS varies between the CNS-PINK risk group (training queue p 0.001, validation queue p-0.038)In the validation queue, the incidence of CNS recurrence in patients in the high-risk CNS-PINK group treated with the SMILE or SMILE-like protocol (S-ID-MTX) containing ID-MTX was lower than in patients receiving treatment without ID-MTX (p-0.029)has been verified to have a strong ABILITy of CNS recurrence prediction in ENKTL patients The effectiveness of S-IR-MTX in preventing CNS events in high-risk CNS-PINK patients should be further verified by further research